Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 7/20 | 0.70 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.55 |
| ▸ | KDM5A | P29375 | 2/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901724 | 0.90 | KMO (0.64) | KMOKDM4CKDM5AKDM5BHPGDS | |
| SCHEMBL4890510 | 0.90 | KMO (0.68) | KMOKDM4CKDM5AKDM5BHPGDS | |
| SCHEMBL4903205 | 0.90 | KMO (0.57) | KMOKDM4CKDM5AKDM5BABL1 | |
| SCHEMBL4897836 | 0.85 | KMO (0.58) | KMOKDM4CKDM5AKDM5BHPGDS | |
| SCHEMBL4901056 | 0.85 | MAPK8 (0.57) | KMOKDM4CABL1BCRPRKCA | |
| SCHEMBL28547944 | 0.85 | KMO (0.63) | KMOHPGDS | |
| SCHEMBL4900461 | 0.83 | KMO (0.70) | KMOKDM4CKDM5AKDM5BABL1 | |
| SCHEMBL4900014 | 0.82 | KMO (0.72) | KMOKDM4CABL1BCRPRKCA | |
| SCHEMBL4901822 | 0.82 | MAOA (0.62) | KMOKDM4CKDM5AKDM5BABL1 | |
| SCHEMBL4899579 | 0.82 | MEN1 (0.56) | KMOKDM4CKDM5AKDM5BABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1799212-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044505-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | KMO 4583/4885KDM4C 3877/4885KDM5A 3488/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | KMO 4622/4885KDM4C 3689/4885KDM5A 3313/4885 |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | KMO 4060/4885KDM4C 1414/4885KDM5A 1189/4885 |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | KMO 4060/4885KDM4C 1414/4885KDM5A 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.